Matthew R. Lowerison

This paper demonstrates the stabilization of gas in aqueous environments using metal-organic frameworks to enable persistent acoustic transduction for long-term ultrasound-biological interfacing.

This study establishes and validates an awake longitudinal fUS-ULM-fULM framework in mice over five months, showing no significant longitudinal drift and no memory impairment or chronic neuroinflammation.

This paper introduces a panoramic PA-US imaging platform that improves resolution and accuracy in whole-body functional and molecular imaging.

This paper develops a microbubble track-based method to improve functional ultrasound localization microscopy's sensitivity in awake mice without sacrificing spatial resolution.

This paper introduces backscattering fULM (B-fULM) to improve 3D functional ultrasound imaging sensitivity by integrating microbubble amplitude with count-based localization.

This paper develops NIR imaging and optogenetic tools using Blvra-/- knockout to enhance light-controlled transcription and in vivo glucose regulation.

This paper introduces a deep learning method using a bi-directional LSTM network to improve microbubble tracking in ULM, validated on simulations, phantoms, and in vivo mouse and rat brains.

This paper introduces a combined imaging technique using ultrasound localization microscopy and nanodrop imaging to detect intracerebral hemorrhage in rodent models.

This paper demonstrates that high-frequency ultrasound localization microscopy improves microvascular imaging fidelity and efficiency in mouse brains.

This study uses ultrasound localization microscopy to image cerebrovascular impairments in a mouse model of Alzheimer's disease, finding early functional vascular changes precede structural derangements.

This study uses Ultrasound Localization Microscopy to quantify aging-related changes in cerebral microvascular dynamics in living mice, finding reduced blood velocity, increased tortuosity, and decreased blood volume in the cortex.

This study identifies RXRA as a therapeutic target for doxorubicin-induced cardiomyopathy in zebrafish by showing its endothelial-specific function and response to FDA-approved agonists.